Moments ago, ANI PHARMS announced FDA approval for its generic version of the unnamed substance, expected to broaden the company’s revenue streams and drive market share expansion within the sector. This significant regulatory clearance is likely to position ANI PHARMS as a formidable competitor by capitalizing on widened market opportunities following product launch.